✦ LIBER ✦

Transdermal selegiline and intravenous cocaine: safety and interactions

✍ Scribed by ElisabethJ. Houtsmuller; LisaD. Notes; Thomas Newton; Nicolette Sluis; Nora Chiang; Ahmed Elkashef; GeorgeE. Bigelow

Book ID: 105880582
Publisher: Springer
Year: 2003
Tongue: English
Weight: 276 KB
Volume: 172
Category: Article
ISSN: 0033-3158
DOI: 10.1007/s00213-003-1616-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Selegiline transdermal system: Current a

Selegiline transdermal system: Current awareness and promise

✍ Chi-Un Pae; Hyun-Kook Lim; Changsu Han; Ajwani Neena; Chul Lee; Ashwin A. Patkar 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 299 KB

The selegiline transdermal system in maj

The selegiline transdermal system in major depressive disorder: A systematic review of safety and tolerability

✍ Donald S. Robinson; Jay D. Amsterdam 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 168 KB

TRANSDERMAL SELEGILINE AND DIETARY TYRAM

TRANSDERMAL SELEGILINE AND DIETARY TYRAMINE: IS THERE A CONCERN?

✍ B.J. McCabe; B.J. Gurley 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 47 KB

Interaction between pethidine and selegi

Interaction between pethidine and selegiline

✍ Starr, Cynthia 📂 Article 📅 1991 🏛 The Lancet 🌐 English ⚖ 286 KB

Assessment of safety, cardiovascular and

Assessment of safety, cardiovascular and subjective effects after intravenous cocaine and lofexidine

✍ De La Garza, R.; Galloway, G.P.; Newton, T.F.; Mendelson, J.; Haile, C.N.; Dib, 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 474 KB

Integrated pharmacokinetic and metabolic

Integrated pharmacokinetic and metabolic modeling of selegiline and metabolites after transdermal administration

✍ Shashank Rohatagi; Jeffrey S. Barrett; Kimberly E. Dewitt; Richard J. Morales 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 249 KB 👁 2 views

Selegiline (SEL) is a selective, irreversible inhibitor of MAO-B, used in the treatment of Parkinson's disease, either alone or as an adjunct to L-DOPA. Selegiline hydrochloride (HCl) undergoes significant first-pass metabolism following oral administration. Transdermal delivery avoids the first-pas